The 10 most recent market catalysts affecting $FHTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 55
Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
Foghorn Therapeutics issued a routine 8-K filing to disclose its third-quarter 2026 financial and corporate update, accompanying its 10-Q. This filing primarily serves as an offici…
Oct 2, 2026
Corporate Catalyst
Bearish
Impact 75
Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2
Wedbush analyst Robert Driscoll downgraded Foghorn Therapeutics (FHTX) from Outperform to Neutral and slashed the price target from $10 to $2. This move signals a significant loss …
Oct 2, 2026
Corporate Catalyst
Bearish
Impact 75
Foghorn Therapeutics shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.
The lowering of price targets by multiple analyst firms signals a significant shift in market sentiment and expectations for Foghorn Therapeutics. This typically occurs when analys…
Oct 1, 2026
Corporate Catalyst
Bearish
Impact 85
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
Foghorn Therapeutics (FHTX) announced the termination of its collaboration with Eli Lilly (LLY) for the FHD-909 program and other discovery efforts, following disappointing Phase 1…
Oct 1, 2026
Corporate Catalyst
Bearish
Impact 85
Foghorn Therapeutics shares are trading lower after the company and Lilly decided not to advance FHD-909 into the expansion phase and discontinued their SMARCA2 degrader collaboration.
The discontinuation of FHD-909 and the SMARCA2 degrader collaboration with Lilly is a major negative catalyst for Foghorn Therapeutics. This drug candidate was a significant part o…
Oct 1, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Thursday's Pre-Market Session
This filing, while presented as an 8-K, is actually a Benzinga article summarizing pre-market stock movements in the healthcare sector. It highlights 12 specific health care stocks…
Oct 1, 2026
Corporate Catalyst
Neutral
Impact 85
Foghorn Therapeutic Announces That The Company And Lilly Will Not Advance The FHD-909 Program Into The Clinical Development Expansion Phase
Foghorn Therapeutics and Eli Lilly have announced the termination of their collaboration, ceasing further development of the FHD-909 and Selective SMARCA2 degrader programs. This d…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Foghorn Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline signals a strong positive corporate catalyst for Foghorn Therapeutics. Better-than-expected financial results typically lead to increased investor confidence, driving…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.